Neuropathological Mechanisms of Alzheimer's Disease: Complications and Potential Treatments
DOI:
https://doi.org/10.47611/jsrhs.v12i4.5645Keywords:
Alzheimer's Disease, Mechanisms, Neurodegenerative, Tau, Amyloid, TreatmentsAbstract
Alzheimer’s Disease (AD) is a neurodegenerative disorder that targets the brain and disrupts vital processes of neural networks causing the decline of cognitive function. The main pathological mechanisms responsible for the development of Alzheimer’s are the tau and amyloid-beta proteins. These proteins are detrimental because they form plaque and neurofibrillary tangles that aggregate within the brain. Biomarkers and diagnostic tools are utilized to detect Alzheimer’s within a patient. These devices can potentially detect the onset of Alzheimer’s early, reducing the severity of symptoms. Throughout studies of various research articles, certain potential AD treatments were analyzed to determine their efficacy. Galantamine was found to be a potent inhibitor of acetylcholinesterase and more effective than rivastigmine and donepezil. A controversial herbal supplement, Ginkgo Biloba, was examined to determine its relevance in reducing the severity of Alzheimer’s. Research findings support that the supplement's efficacy is inconclusive as trials have not been able to provide significant evidence as to whether or not Ginkgo Biloba is effective in the case of Alzheimer’s. By investigating the impact of prospective treatments on the mechanisms of Alzheimer’s, this extensive research aims to provide evidence to handle the effects of the disease and determine significant treatments to ensure the quality of healthcare for all patients distressed by Alzheimer’s Disease.
Downloads
References or Bibliography
Bermingham, S. (2014). The Appropriate Use of Neuroimaging in the Diagnostic Work-Up of Dementia: An Economic Literature Review and Cost-Effectiveness Analysis. PubMed Central (PMC). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3937984/
Birks, J., & Evans, J. G. (2015). Rivastigmine for Alzheimer’s disease. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd001191.pub3
Chow, V. W., Mattson, M. P., Wong, P. C., & Gleichmann, M. (2009). An overview of APP processing enzymes and products. Neuromolecular Medicine, 12(1), 1–12. https://doi.org/10.1007/s12017-009-8104-z
Cukalevski, R., Boland, B., Frohm, B., Thulin, E., Walsh, D. M., & Linse, S. (2012). Role of aromatic side chains in amyloid Β-Protein aggregation. ACS Chemical Neuroscience, 3(12), 1008–1016. https://doi.org/10.1021/cn300073s
De La Rosa, A., Olaso-Gonzalez, G., Arc-Chagnaud, C., Millán, F., Salvador-Pascual, A., García-Lucerga, C., Blasco-Lafarga, C., García-Domínguez, E., Carretero, A., Correas, Á. G., Viña, J., & Gómez-Cabrera, M. C. (2020). Physical exercise in the prevention and treatment of Alzheimer’s disease. Journal of Sport and Health Science, 9(5), 394–404. https://doi.org/10.1016/j.jshs.2020.01.004
Djikaev, Y. S., & Ruckenstein, E. (2010). A probabilistic approach to the effect of water hydrogen bonds on the kinetics of protein folding and protein denaturation. Advances in Colloid and Interface Science, 154(1–2), 77–90. https://doi.org/10.1016/j.cis.2010.01.009
Dong, Z., Yang, X., Chang, L., Song, X., Li, X., Wang, J., & Li, J. (2021). Influence of MRI on Diagnostic Efficacy and Satisfaction of Patients with Alzheimer’s Disease. Computational and Mathematical Methods in Medicine, 2021, 1–6. https://doi.org/10.1155/2021/9038784
Guo, X., Wang, Z., Li, K., Li, Z., Qi, Z., Zhou, J., Yao, L., & Chen, K. (2010b). Voxel-based assessment of gray and white matter volumes in Alzheimer’s disease. Neuroscience Letters, 468(2), 146–150. https://doi.org/10.1016/j.neulet.2009.10.086
Hamano, T., Enomoto, S., Shirafuji, N., Ikawa, M., Yamamura, O., Yen, S. H., & Nakamoto, Y. (2021). Autophagy and tau protein. International Journal of Molecular Sciences, 22(14), 7475. https://doi.org/10.3390/ijms22147475
Hansen, R. A. (2008, June 1). Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: A systematic review and meta-analysis. PubMed Central (PMC). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2546466/
Hippius, H., & Neundörfer, G. (2003). The discovery of Alzheimer’s disease. Dialogues in Clinical Neuroscience, 5(1), 101–108. https://doi.org/10.31887/dcns.2003.5.1/hhippius
Hoskin, J. L., Al-Hasan, Y., & Sabbagh, M. N. (2018). Nicotinic acetylcholine receptor Agonists for the treatment of Alzheimer’s dementia: an update. Nicotine & Tobacco Research, 21(3), 370–376. https://doi.org/10.1093/ntr/nty116
How biomarkers help diagnose dementia. (n.d.). National Institute on Aging. https://www.nia.nih.gov/health/how-biomarkers-help-diagnose-dementia
Johnson, K. A., Fox, N. C., Sperling, R. A., & Klunk, W. E. (2012). Brain imaging in Alzheimer disease. Cold Spring Harbor Perspectives in Medicine, 2(4), a006213. https://doi.org/10.1101/cshperspect.a006213
Liu, X., Ye, M., & Ma. (2022). The emerging role of autophagy and mitophagy in tauopathies: From pathogenesis to translational implications in Alzheimer’s disease. Frontiers in Aging Neuroscience, 14. https://doi.org/10.3389/fnagi.2022.1022821
Mallamace, D., Fazio, E., Mallamace, F., & Corsaro, C. (2018). The role of hydrogen bonding in the Folding/Unfolding Process of hydrated lysozyme: A review of recent NMR and FTIR results. International Journal of Molecular Sciences, 19(12), 3825. https://doi.org/10.3390/ijms19123825
Medeiros, R., Baglietto-Vargas, D., & LaFerla, F. M. (2010). The role of TAU in Alzheimer’s disease and related disorders. CNS Neuroscience & Therapeutics, 17(5), 514–524. https://doi.org/10.1111/j.1755-5949.2010.00177.x
Murphy, M. P., & LeVine, H. (2010). Alzheimer’s disease and the amyloid-Β peptide. Journal of Alzheimer’s Disease, 19(1), 311–323. https://doi.org/10.3233/jad-2010-1221
Nebel, R. A., Aggarwal, N. T., Barnes, L. L., Gallagher, A. M., Goldstein, J. M., Kantarci, K., Mallampalli, M. P., Mormino, E. C., Scott, L. L., Yu, W. H., Maki, P. M., & Mielke, M. M. (2018). Understanding the impact of sex and gender in Alzheimer’s disease: A call to action. Alzheimers & Dementia, 14(9), 1171–1183. https://doi.org/10.1016/j.jalz.2018.04.008
Oken, B., Storzbach, D., & Kaye, J. (1998). The Efficacy of Ginkgo biloba on Cognitive Function in Alzheimer Disease. Archives of Neurology, 55(11), 1409. https://doi.org/10.1001/archneur.55.11.1409
Patterson, C., Feightner, J., Garcia, A., Hsiung, G. R., MacKnight, C., & Sadovnick, A. D. (2008). Diagnosis and treatment of dementia: 1. Risk assessment and primary prevention of Alzheimer disease. Canadian Medical Association Journal, 178(5), 548–556. https://doi.org/10.1503/cmaj.070796
Porsteinsson, A. P., Isaacson, R. S., Knox, S., Sabbagh, M. N., & Rubino, I. (2021). Diagnosis of Early Alzheimer’s Disease: Clinical Practice in 2021. JPAD, 1–16. https://doi.org/10.14283/jpad.2021.23
Reiss, A. B., Arain, H. A., Stecker, M. M., Siegart, N., & Kasselman, L. J. (2018). Amyloid toxicity in Alzheimer’s disease. Reviews in the Neurosciences, 29(6), 613–627. https://doi.org/10.1515/revneuro-2017-0063
Šerý, O., Povová, J., Míšek, I., Pešák, L., & Janout, V. (2013). Molecular mechanisms of neuropathological changes in Alzheimer’s disease: a review. Folia Neuropathologica, 1, 1–9. https://doi.org/10.5114/fn.2013.34190
Published
How to Cite
Issue
Section
Copyright (c) 2023 Vineel Gavini; Mrs. Jothsna Kethar, Dr. Rajagopal Appavu
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright holder(s) granted JSR a perpetual, non-exclusive license to distriute & display this article.
